Amgen, Genentech Await Del. Ruling In Biosimilar IP Row
A California federal judge on Thursday tentatively paused Amgen's suit seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, saying he wanted to see whether a...To view the full article, register now.
Already a subscriber? Click here to view full article